AU764348B2 - Methods for administration of antibiotics - Google Patents

Methods for administration of antibiotics Download PDF

Info

Publication number
AU764348B2
AU764348B2 AU62687/99A AU6268799A AU764348B2 AU 764348 B2 AU764348 B2 AU 764348B2 AU 62687/99 A AU62687/99 A AU 62687/99A AU 6268799 A AU6268799 A AU 6268799A AU 764348 B2 AU764348 B2 AU 764348B2
Authority
AU
Australia
Prior art keywords
dose
daptomycin
use according
administered
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU62687/99A
Other languages
English (en)
Other versions
AU6268799A (en
Inventor
Frederick B. Oleson Jr.
Francis P. Tally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU764348(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Publication of AU6268799A publication Critical patent/AU6268799A/en
Application granted granted Critical
Publication of AU764348B2 publication Critical patent/AU764348B2/en
Assigned to CUBIST PHARMACEUTICALS LLC reassignment CUBIST PHARMACEUTICALS LLC Request to Amend Deed and Register Assignors: CUBIST PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU62687/99A 1998-09-25 1999-09-24 Methods for administration of antibiotics Expired AU764348B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US60/101828 1998-09-25
US12575099P 1999-03-24 1999-03-24
US60/125750 1999-03-24
PCT/US1999/022366 WO2000018419A2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Publications (2)

Publication Number Publication Date
AU6268799A AU6268799A (en) 2000-04-17
AU764348B2 true AU764348B2 (en) 2003-08-14

Family

ID=26798675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62687/99A Expired AU764348B2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Country Status (26)

Country Link
US (2) US6468967B1 (enExample)
EP (2) EP1674107B8 (enExample)
JP (4) JP4184607B2 (enExample)
KR (2) KR20010075327A (enExample)
CN (2) CN1530136A (enExample)
AT (1) ATE322280T1 (enExample)
AU (1) AU764348B2 (enExample)
BR (1) BR9914051A (enExample)
CA (1) CA2344318C (enExample)
CY (3) CY1105556T1 (enExample)
DE (3) DE122006000049I2 (enExample)
DK (2) DK1115417T3 (enExample)
ES (2) ES2603086T3 (enExample)
HK (1) HK1040363B (enExample)
HU (1) HU230656B1 (enExample)
IS (2) IS5890A (enExample)
LU (1) LU91254I2 (enExample)
NL (1) NL300232I2 (enExample)
NO (1) NO20011454L (enExample)
NZ (1) NZ510690A (enExample)
PL (2) PL203689B1 (enExample)
PT (2) PT1674107T (enExample)
RU (1) RU2363489C9 (enExample)
SI (2) SI1674107T1 (enExample)
TR (1) TR200100841T2 (enExample)
WO (1) WO2000018419A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
US6911525B2 (en) 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
AU2002246688A1 (en) * 2000-12-18 2002-07-30 Altus Biologics Inc. Methods for preparing purified daptomycin
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CA2713989A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP3632459A1 (en) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010048630A1 (en) * 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
RU2512396C2 (ru) 2008-12-22 2014-04-10 Кьюбист Фармасьютикалз, Инк. Новые противобактериальные средства для лечения грамположительных инфекций
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
WO2011008193A1 (en) * 2009-07-13 2011-01-20 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
EP3569235A1 (en) 2009-09-04 2019-11-20 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
BR112012012406B1 (pt) 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
DE13837694T1 (de) * 2012-09-11 2015-12-31 Hospira Australia Pty Ltd. Daptomycinformulierungen und Verwendungen davon
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
KR102237887B1 (ko) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386951A2 (en) * 1989-03-06 1990-09-12 Eli Lilly And Company An improved diluent formulation for daptomycin
WO1998022107A1 (fr) * 1996-11-19 1998-05-28 Rhone-Poulenc Rorer S.A. Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AU1568999A (en) * 1997-12-16 1999-07-05 Aventis Pharma S.A. Pharmaceutical compositions based on dalforpristin and quinupristin and preparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386951A2 (en) * 1989-03-06 1990-09-12 Eli Lilly And Company An improved diluent formulation for daptomycin
WO1998022107A1 (fr) * 1996-11-19 1998-05-28 Rhone-Poulenc Rorer S.A. Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AU1568999A (en) * 1997-12-16 1999-07-05 Aventis Pharma S.A. Pharmaceutical compositions based on dalforpristin and quinupristin and preparation

Also Published As

Publication number Publication date
ES2603086T3 (es) 2017-02-23
NL300232I2 (nl) 2007-01-02
US6468967B1 (en) 2002-10-22
PL348328A1 (en) 2002-05-20
WO2000018419A2 (en) 2000-04-06
NO20011454D0 (no) 2001-03-22
US20020142948A1 (en) 2002-10-03
PT1115417E (pt) 2006-07-31
CY2006003I2 (el) 2009-11-04
JP2003321389A (ja) 2003-11-11
EP1674107B8 (en) 2017-01-25
PL206091B1 (pl) 2010-06-30
HUP0103874A2 (hu) 2002-02-28
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
RU2004106569A (ru) 2005-08-10
US6852689B2 (en) 2005-02-08
JP2004339238A (ja) 2004-12-02
HK1040363B (en) 2007-01-26
PL203689B1 (pl) 2009-11-30
JP2002525335A (ja) 2002-08-13
KR20100051735A (ko) 2010-05-17
CA2344318A1 (en) 2000-04-06
HUP0103874A3 (en) 2002-09-30
EP1674107B1 (en) 2016-08-24
NL300232I1 (nl) 2006-09-01
ATE322280T1 (de) 2006-04-15
CA2344318C (en) 2006-07-04
ES2259845T3 (es) 2006-10-16
HK1040363A1 (en) 2002-06-07
KR20010075327A (ko) 2001-08-09
SI1674107T1 (sl) 2017-01-31
DE69930758T2 (de) 2007-04-26
CY1105556T1 (el) 2010-07-28
IS8807A (is) 2009-03-10
EP1674107A3 (en) 2012-06-20
EP1674107A2 (en) 2006-06-28
CN1150029C (zh) 2004-05-19
DK1115417T3 (da) 2006-07-31
SI1115417T1 (sl) 2006-08-31
JP4184607B2 (ja) 2008-11-19
NZ510690A (en) 2002-10-25
LU91254I2 (fr) 2006-08-28
CY2006003I1 (el) 2009-11-04
TR200100841T2 (tr) 2002-01-21
CN1530136A (zh) 2004-09-22
JP2006335773A (ja) 2006-12-14
DK1674107T3 (en) 2016-12-19
EP1674107A8 (en) 2006-10-04
RU2363489C9 (ru) 2010-03-20
WO2000018419A3 (en) 2000-07-06
NO20011454L (no) 2001-05-25
AU6268799A (en) 2000-04-17
DE69930758D1 (de) 2006-05-18
DE122006000049I2 (de) 2007-11-08
PT1674107T (pt) 2016-12-07
BR9914051A (pt) 2001-06-19
CN1348382A (zh) 2002-05-08
RU2363489C2 (ru) 2009-08-10
IS5890A (is) 2001-03-14
DE122006000049I1 (de) 2007-01-04
EP1115417B1 (en) 2006-04-05
HU230656B1 (hu) 2017-06-28

Similar Documents

Publication Publication Date Title
AU764348B2 (en) Methods for administration of antibiotics
Raja et al. Daptomycin
Tedesco et al. Daptomycin
Tally et al. Daptomycin: a novel agent for Gram-positive infections
Nigo et al. What’s new in the treatment of enterococcal endocarditis?
Lin et al. Dalbavancin: a new option for the treatment of gram-positive infections
CA2591157C (en) Antibiotic combinations for providing total solution to the treatment of infections
Leonard et al. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram‐positive infections
US20190388417A1 (en) Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
ZA200102389B (en) Methods for administration of antibiotics.
HK1094672A (en) Use of daptomycin
CZ20011014A3 (cs) Farmaceutické přípravky obsahující lipoproteinová antibiotika
Ross et al. Glycopeptide pharmacodynamics
Sun et al. Daptomycin
Hermsen et al. Glycopeptide pharmacodynamics
Jacqueline et al. Antibiotics Against Endocarditis–Past, Present and Future (Experimental Data)
Shankar et al. Newer antibiotics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired